Journal
MOLECULAR CARCINOGENESIS
Volume 54, Issue 12, Pages 1815-1819Publisher
WILEY
DOI: 10.1002/mc.22252
Keywords
acute myeloid leukemia; chemotherapy resistance; relapse; EVI1; CADM1
Categories
Funding
- Austrian Science Foundation [P-20920, P-19795]
- German Research Council [SFB873]
- Austrian Science Fund (FWF) [P 20920, P 24130] Funding Source: researchfish
- Austrian Science Fund (FWF) [P24130] Funding Source: Austrian Science Fund (FWF)
Ask authors/readers for more resources
Even though a large proportion of patients with acute myeloid leukemia (AML) achieve a complete remission upon initial therapy, the majority of them eventually relapse with resistant disease. Overexpression of the gene coding for the transcription factor Ecotropic Virus Integration site 1 (EVI1) is associated with rapid disease recurrence and shortened survival. We therefore sought to identify EVI1 target genes that may play a role in chemotherapy resistance using a previously established in vitro model system for EVI1 positive myeloid malignancies. Gene expression microarray analyses uncovered the Cell Adhesion Molecule 1 (CADM1) gene as a candidate whose deregulation by EVI1 may contribute to drug refractoriness. CADM1 is an apoptosis inducing tumor suppressor gene that is inactivated by methylation in a variety of tumor types. In the present study we provide evidence that it may play a role in chemotherapy induced cell death in AML: CADM1 was induced by drugs used in the treatment of AML in a human myeloid cell line and in primary diagnostic AML samples, and its experimental expression in a cell line model increased the proportion of apoptotic cells. CADM1 up-regulation was abolished by ectopic expression of EVI1, and EVI1 expression correlated with increased CADM1 promoter methylation both in a cell line model and in primary AML cells. Finally, CADM1 induction was repressed in primary samples from AML patients at relapse. In summary, these data suggest that failure to up-regulate CADM1 in response to chemotherapeutic drugs may contribute to therapy resistance in AML. (c) 2014 The Authors. Molecular Carcinogenesis published by Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available